Table 2. Estimates of non-compliance with HIV clinical care guidelines by gender.γ .
| Gender | |||
| Women (n = 745) | Men (n = 2897) | p-value | |
| Indicators at baseline | |||
| (1) Not having drug resistance testing prior to starting treatment | |||
| Yes, n (%) | 310 (42) | 995 (34) | <0.001 |
| No, n (%) | 435 (58) | 1902 (66) | |
| (2) Starting on a non-recommended ART regimen | |||
| Yes, n (%) | 126 (17) | 256 (9) | <0.001 |
| No, n (%) | 619 (83) | 2641 (91) | |
| (3) Starting therapy with CD4 less than 200 cells/mm3 | |||
| Yes, n (%) | 347 (47) | 1413 (49) | 0.284 |
| No, n (%) | 398 (53) | 1484 (51) | |
| Indicators during the first-year of follow-up | |||
| (4) Receiving less than 3 CD4 cell count tests | |||
| Yes, n (%) | 124 (17) | 312 (11) | <0.001 |
| No, n (%) | 621 (83) | 2585 (89) | |
| (5) Receiving less than 3 plasma viral load tests | |||
| Yes, n (%) | 124 (17) | 312 (11) | <0.001 |
| No, n (%) | 621 (83) | 2585 (89) | |
| (6) Not achieving HIV viral load suppression within six months of treatment initiation | |||
| Yes, n (%) | 375 (50) | 1178 (41) | <0.001 |
| No, n (%) | 370 (50) | 1719 (59) | |
γ
Overall, QOC was better among men, who had a lower mean PCS score of 1.54 (SD = 1.30) compared with 1.89 (SD = 1.37) for women.